Latest Vaccines Stories
How well people are protected by the smallpox vaccine depends on more than the quality of the vaccination: individual genes can alter their response, Mayo Clinic research shows. The findings, gathered using sophisticated genomic screening, appear in today's online issue of the journal Genes and Immunity. "We were looking into the intercellular reactions that occur when vaccinated and unvaccinated persons are exposed to and infected with smallpox virus. We were able to use blood samples...
All 3 configurations of adjuvant and route of administration exceeded the 3 CHMP criteria IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs),...
LONDON, April 18, 2013 /PRNewswire/ -- Replikins Ltd will reveal details on the availability of two completely synthetic vaccine candidates, both with long-term prevention goals and acute short-term blocking capacity. One of these vaccines targets H7N9 alone, the other for H7N9 plus the other common influenza strains. The company is exploring partnerships with established healthcare and pharmaceutical companies to aggressively commercialize the technology. Because Replikins is...
-- Efficacy and Safety Data for EV71 Vaccine Discussed in Presentation by Deputy Director of Jiangsu Provincial CDC BEIJING, April 18, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today that Fengcai Zhu, Deputy Director of the Jiangsu Provincial Center for Disease Prevention and Control, presented data regarding Sinovac's proprietary enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD") at the...
BEIJING, April 18, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, announced today that it has received the Certificate of Approval to commercialize seasonal flu vaccine in Mexico by the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) of the Mexico Ministry of Health. The certificate of commercial approval is valid from April 1, 2013 to April 1, 2018. The Company filed the application to distribute Anflu in...
Biotech recognized for VGX-3100, an innovative therapy for pre-cancers and cancers caused by HPV, now in phase II for cervical dysplasia BLUE BELL, Pa., April 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it was presented Vaccine Industry Excellence (ViE) Awards for "Best Therapeutic Vaccine" and "Best Early Stage Biotech" at the World Vaccine Congress, which is being held this week in Washington, D.C. The ViE Awards recognize outstanding...
- All three configurations of adjuvant and route of administration exceeded the three CHMP criteria- QUEBEC CITY, and SEATTLE, WA, April 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs) and The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is...
- All three configurations of adjuvant and route of administration exceeded the three CHMP criteria- SEATTLE and QUEBEC CITY, April 17, 2013 /PRNewswire-USNewswire/ -- IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines...
LAWRENCEBURG, Ind., April 16, 2013 /PRNewswire/ -- PDS Biotechnology Corporation today presented a summary of the company's preclinical data on its lead cancer immunotherapy PDS0101 at the World Vaccine Congress in Washington DC. The product is based on the company's ground-breaking and proprietary Versamune(TM) nanotechnology vaccine platform. PDS Biotechnology also announced that the company's Investigational New Drug (IND) application had been granted by the FDA allowing PDS0101...
PROVIDENCE, R.I., April 13, 2013 /PRNewswire/ -- Full Story - http://bit.ly/H7N9EpiVax The H7N9 emerging from China is a stealth virus. State of the art bioinforamatics tools have enabled EpiVax to predict that it will be hard to make vaccines and diagnostics for the new H7N9 flu virus (also called H7N9A/Shanghai/1/2013). H7N9 has fewer T cell epitopes than most previously circulating strains of flu, meaning that it may be able to fly under the immune system's radar. Making a rapid...
Latest Vaccines Reference Libraries
Neisseria meningitidis is a heterotrophic gram-negative diplococcal bacterium best known for its role in meningitis and other forms of meningococcal disease such as meningococcemia. It is a major cause of morbidity and mortality during childhood in industrialized countries and is responsible for epidemics in Africa and in Asia. In the US there are approximately 2500 to 3500 cases of N. meningitides infections. Children under 5 are at a higher risk as well as people in the sub-Saharan...
Poliovirus, the causative agent of poliomyelitis and a member of the family of Picornaviridae, is a human enterovirus. It is composed of an RNA genome that is a single-stranded positive-sense RNA. It was first isolate in 1909 and was published in 1981. It is one of the most well characterized viruses and has become a useful model system for understanding the biology of RNA viruses. It infects human cells by binding to an immunoglobulin-like receptor on the cell surface. The three...
